Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCell Technologies, a biopharmaceutical company, has entered into a cooperative R&D agreement with US-based Maxim Biotech, to develop products for the study of liver stem cells and liver cancer.
Subscribe to our email newsletter
The cooperative R&D agreement with Maxim Biotech will initially focus on the development of a family of life science research reagent tool kits which can be used to isolate liver stem cells, and help to elucidate liver stem cell gene function and their encoded proteins.
MultiCell owns exclusive rights to two issued US patents, one patent application and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells.
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell plans to further leverage this research effort involving liver stem cells to identify therapeutic targets, and diagnostic and prognostic markers of liver cancer.
MultiCell will also seek to develop and patent therapeutic product opportunities specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer.